Columnist: New technology undercutting Home Diagnostic's IPO

06/30/2006 | Forbes

Home Diagnostics' co-branding strategy has worked well to sell its line of blood glucose monitors, but new continuous-monitoring technologies being offered by DexCom, Cygnus and Medtronic could undermine the firm's planned IPO, according to Forbes columnist Scott Reeves.

View Full Article in:

Forbes

Published in Brief:

SmartBrief Job Listings for Health Care